JP2018538367A - ホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）の心臓疾患を治療するための標的設定 - Google Patents

ホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）の心臓疾患を治療するための標的設定 Download PDF

Info

Publication number
JP2018538367A
JP2018538367A JP2018545568A JP2018545568A JP2018538367A JP 2018538367 A JP2018538367 A JP 2018538367A JP 2018545568 A JP2018545568 A JP 2018545568A JP 2018545568 A JP2018545568 A JP 2018545568A JP 2018538367 A JP2018538367 A JP 2018538367A
Authority
JP
Japan
Prior art keywords
alx
fpr2
treatment
receptor
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018545568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018538367A5 (OSRAM
Inventor
ジャセク・オストロウスキー
リカルド・ガルシア
ニコラス・アール・ワーツ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2018538367A publication Critical patent/JP2018538367A/ja
Publication of JP2018538367A5 publication Critical patent/JP2018538367A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018545568A 2015-11-24 2016-11-21 ホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）の心臓疾患を治療するための標的設定 Withdrawn JP2018538367A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562259498P 2015-11-24 2015-11-24
US62/259,498 2015-11-24
PCT/US2016/063036 WO2017091496A1 (en) 2015-11-24 2016-11-21 Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease

Publications (2)

Publication Number Publication Date
JP2018538367A true JP2018538367A (ja) 2018-12-27
JP2018538367A5 JP2018538367A5 (OSRAM) 2019-12-19

Family

ID=57544530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018545568A Withdrawn JP2018538367A (ja) 2015-11-24 2016-11-21 ホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）の心臓疾患を治療するための標的設定

Country Status (13)

Country Link
US (1) US20180325869A1 (OSRAM)
EP (1) EP3380091A1 (OSRAM)
JP (1) JP2018538367A (OSRAM)
KR (1) KR20180081528A (OSRAM)
CN (1) CN108348479A (OSRAM)
AU (1) AU2016359463A1 (OSRAM)
BR (1) BR112018010155A8 (OSRAM)
CA (1) CA3006291A1 (OSRAM)
EA (1) EA201891007A1 (OSRAM)
IL (1) IL259468A (OSRAM)
MX (1) MX2018005756A (OSRAM)
SG (1) SG11201803816RA (OSRAM)
WO (1) WO2017091496A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102772801B1 (ko) 2015-12-10 2025-02-24 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
CN110997661B (zh) 2017-06-09 2023-03-31 百时美施贵宝公司 环丙基脲甲酰肽2受体和甲酰肽1受体激动剂
US11186544B2 (en) 2017-06-09 2021-11-30 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
KR102615095B1 (ko) * 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 효능제
KR102615099B1 (ko) 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
MY204384A (en) 2018-03-05 2024-08-27 Bristol Myers Squibb Co Phenylpyrrolidinone formyl peptide 2 receptor agonists
US12281108B2 (en) 2018-11-26 2025-04-22 Bristol-Myers Squibb Company Pyrrolidinone derivatives as formyl peptide 2 receptor agonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2225231B1 (en) * 2007-12-18 2011-08-17 Actelion Pharmaceuticals Ltd. Aminotriazole derivatives as alx agonists
WO2012066488A2 (en) * 2010-11-17 2012-05-24 Actelion Pharmaceuticals Ltd Bridged spiro[2.4]heptane ester derivatives
CN104284887B (zh) * 2012-05-16 2016-06-22 埃科特莱茵药品有限公司 作为alx受体激动剂的经1-(对-甲苯基)环丙基取代的桥联螺[2.4]庚烷衍生物
KR102772801B1 (ko) * 2015-12-10 2025-02-24 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
MY204384A (en) * 2018-03-05 2024-08-27 Bristol Myers Squibb Co Phenylpyrrolidinone formyl peptide 2 receptor agonists

Also Published As

Publication number Publication date
KR20180081528A (ko) 2018-07-16
BR112018010155A8 (pt) 2019-02-26
CN108348479A (zh) 2018-07-31
IL259468A (en) 2018-07-31
WO2017091496A1 (en) 2017-06-01
SG11201803816RA (en) 2018-06-28
BR112018010155A2 (pt) 2018-11-21
EA201891007A1 (ru) 2018-11-30
MX2018005756A (es) 2018-08-01
AU2016359463A1 (en) 2018-07-12
CA3006291A1 (en) 2017-06-01
US20180325869A1 (en) 2018-11-15
EP3380091A1 (en) 2018-10-03

Similar Documents

Publication Publication Date Title
JP2018538367A (ja) ホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）の心臓疾患を治療するための標的設定
Wang et al. Coriolus versicolor alleviates diabetic cardiomyopathy by inhibiting cardiac fibrosis and NLRP3 inflammasome activation
Liu et al. Rivaroxaban suppresses the progression of ischemic cardiomyopathy in a murine model of diet-induced myocardial infarction
JP6440212B2 (ja) メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
CN107072972B (zh) 用伊非曲班治疗心脏纤维化的组合物和方法
KR102354243B1 (ko) 트롬복산-a2 수용체 길항제를 이용한 근위축증 치료 조성물 및 방법
KR20140022052A (ko) 심근 경색 후 환자에서의 심부전 및 부정맥 치료를 위한 ａ２ｂ 아데노신 수용체 안타고니스트의 용도
JP2020520948A (ja) 心不全の治療用のホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）アゴニストの新規な使用
EP3448309A1 (en) Ifetroban treatment for systemic sclerosis
US10172914B2 (en) Combination
US20190054077A1 (en) Compounds, compositions and methods for preventing and/or treating chlorine inhalation toxicity and/or injury
US20250152671A1 (en) Medical composition for treating patients exhibiting cardiac decompensation
US20230114408A1 (en) Methods of modulating t-cell activation using estrogen receptor beta (erb) agonists
CN104220083A (zh) 用于治疗动脉硬化性血管疾病的方法和组合物
Mommsen et al. Productive capacity of alveolar macrophages and pulmonary organ damage after femoral fracture and hemorrhage in IL-6 knockout mice
EP4117660B1 (en) Methods of modulating t-cell activation and treating chronic heart failure using carboranes
JP7233087B2 (ja) 抗動脈硬化剤
KR20190013509A (ko) Nep 저해제 및 베타-차단제를 포함하는 약제학적 조성물
HK40080138A (en) Methods of modulating t-cell activation using carboranes and carborane analogs
WO2024073499A2 (en) Compositions and methods for treating graft-related arrhythmia
Ortega et al. NLRP3 inflammasome as a therapeutic target in cardiovascular diseases: An update of preclinical and clinical evidence
WO2025056188A1 (en) Relaxin medication
CN116236477A (zh) 溶血磷脂酸受体5拮抗剂在制备心脏保护药物中的应用
Van De Sandt et al. Pharmacological CCR1 blockade limits infarct size, preserves cardiac function and attenuates left ventricular remodeling in a murine model of myocardial ischemia/reperfusion
EP3072514A1 (en) Novel oral anticoagulants (NOACs) for preventing development and aggravation of atrial fibrillation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191106

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20200513